Emergent Biosolutions Inc. said it has secured exclusive right to manufacture and sell VaxInnate Corp.’s pandemic influenza vaccine candidate in the United States.
Under a license agreement with VaxInnate, Emergent Biosolutions acquired exclusive U.S. commercial rights to next generation pandemic influenza vaccine candidate.
This license enables Emergent to fulfill the requirement to secure a pandemic influenza vaccine candidate under its contract with the Biomedical Advanced Research and Development Authority (BARDA), the company noted.
{iframe}http://www.istockanalyst.com/finance/story/6212271/emergent-biosolutions-ebs-acquires-commercial-rights-to-pandemic-influenza-vaccine-candidate{/iframe}